Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Phase 2b Efficacy and Safety Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients (AERODUO-2)

17. november 2026 opdateret af: AeroRx Therapeutics Inc.

Randomized, Double-Blind, Placebo-Controlled, 14-Day Treatment, 2-Period Crossover Trial Evaluating the Lung Function Response After Treatment With Inhaled LABA and LAMA Monotherapies and Their Combination AERO-007 Administered Via Nebulization in Participants With Chronic Obstructive Pulmonary Disease (COPD) (AERODUO-2 Trial)

This is a phase 2b, randomized, double-blind, placebo-controlled, dose-ranging,14-day dosing, 2-period crossover study in participants with chronic obstructive pulmonary disease (COPD).

Studieoversigt

Detaljeret beskrivelse

Combination of a long-acting beta-agonist (LABA) bronchodilator and a long-acting muscarinic antagonist (LAMA) bronchodilator is the preferred choice for initial therapy for patients with chronic obstructive pulmonary disease (COPD). Although there are currently multiple LABA+LAMA combination bronchodilators available in metered dose inhalers (MDIs), dry powder inhalers (DPI), and soft mist inhalers (SMI), a significant percentage of COPD patients, generally high risk and older patients, do not receive optimal benefit from inhalers.

Nebulized delivery provides an effective alternative where disease management is sub optimal. To date there are no approved LABA+LAMA combinations available by nebulization.

AERO-007 is a propriety inhalation solution formulation of fixed-dose combination of LABA+LAMA (indacaterol, AERO-001 and glycopyrrolate, AERO-002) for delivery in a general purpose nebulizer device. A phase 2a, single-dose, dose-ranging study of AERO-007 has been completed in participants with COPD at two dose levels (100/50 µg and 200/100 µg). AERO-007 at both low and high doses was well tolerated with robust, clinically meaningful and statistically significant bronchodilation with rapid onset of action that was sustained for 24 hours.

The objective of this phase 2b study is to determine the optimal doses of the monotherapy components of AERO-007 and to assess the safety, PK and bronchodilation profile of AERO-007 following 14 days of dosing in participants with COPD.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

64

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

      • London, Det Forenede Kongerige
        • Rekruttering
        • Parexel
      • Manchester, Det Forenede Kongerige
        • Rekruttering
        • Medicines Evaluation Unit

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

40 år til 75 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Male or female aged 40 to 75 years, inclusive, at the time of informed consent

  • Clinical diagnosis of COPD according to the Global Initiative for Chronic Obstructive Lung Disease [GOLD] Report, 2026 for at least 12 months prior to Screening Visit 1

  • Post-bronchodilator spirometry (after 10 to 30 minutes following 4 puffs of albuterol via MDI with a spacer) at Screening Visit 2 demonstrating the following:

    • FEV1 > 40 and < 80% of predicted normal (using the Global Lung Function Initiative [GLI] 2012 reference values)
    • FEV1/forced vital capacity (FVC) ratio < 0.70
    • ≥ 150 mL increase from pre-bronchodilator FEV1 following 4 puffs of albuterol
  • Ability to change current COPD therapy and discontinue long-acting bronchodilators, if applicable, for the duration of the trial and short-acting bronchodilators for 8 hours prior to dosing at each Treatment Visit

  • Current or former-smokers with at least 10 pack-year smoking history (eg, at least 1 pack/day for 10 years, 10 packs/day for 1 year)

  • Ability to perform reproducible spirometry according to the American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines

  • Female participants of childbearing potential must not be pregnant, breast feeding or lactating and heterosexual female participants of childbearing potential must agree to use, with their partner, a male condom plus an approved method of highly effective birth control from the time of informed consent and for 30 days following the last administered dose

  • Female participants of childbearing potential must have a negative serum or urine pregnancy test at Screening Visit 1 and a negative urine pregnancy test prior to dosing at each Treatment Visit

  • Male participants who are sexually active with a female partner of childbearing potential must use, with their partner, a male condom plus an approved method of highly effective contraception from the time of informed consent and for 30 days following the last administered dose

  • Participants must agree not to donate semen or ova/oocytes from the time of informed consent and for 30 days following the last administered dose

  • Willing and able to provide written informed consent

Exclusion Criteria:

  • Current evidence or recent history of significant comorbidities; including cardiovascular disease (such as myocardial infarction, cardiac failure, uncontrolled hypertension, or life-threatening arrhythmias), uncontrolled diabetes, neurologic, psychiatric, hepatic, renal, immunological, or hematological conditions within the last 6 months prior to Screening Visit 1
  • Positive serum hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody or human immunodeficiency virus (HIV) type 1 and/or 2 antibodies at Screening Visit 1
  • Lower respiratory tract infection within 6 weeks prior to Screening Visit 1
  • Recent history of hospitalization due to an exacerbation of airway disease or acute worsening of COPD requiring antibiotic or systemic corticosteroid treatment within 6 months prior to Screening Visit 1
  • Other respiratory disorders: Current diagnosis of predominant asthma, lung cancer, bronchiectasis, interstitial lung disease, tuberculosis, pulmonary hypertension, or other non-specific pulmonary diseases
  • Prior lung volume reduction surgery or history of chest/lung irradiation
  • Daily oxygen therapy for > 12 hours per day
  • Body mass index >35 kg/m2
  • Abnormal and clinically significant 12-lead ECG findings at Screening Visit 1
  • Current or recent history of medical conditions that are contraindicated for use of an inhaled LAMA (such as urinary retention or bladder neck obstruction type symptoms, prostatic hypertrophy, or narrow-angle glaucoma) within the last 6 months prior to Screening Visit 1
  • Current or recent history (previous 12 months) of excessive use or abuse of alcohol (males >21 units per week and females >14 units per week)
  • Current evidence or history (within the past 2 years) of abusing legal drugs or use of illegal drugs or substances
  • Donation of 450 mL of blood within 8 weeks of Screening Visit 1
  • Major surgery (requiring general anaesthesia) within 6 weeks prior to Screening Visit 1, or planned surgery through the EOS Visit
  • History of malignancy of any organ system, except for localized skin cancers, within 5 years prior to Screening Visit 1
  • History of intolerance or hypersensitivity to any of the ingredients in the formulation for AERO-001, AERO-002, AERO-007, or other aerosol medications
  • Participation in another investigational drug trial within 30 days of the last dose, 5 half-lives or twice the duration of the biological effect, whichever is longer, prior to Screening Visit 1
  • History or high risk of noncompliance with trial visits and procedures or unsuitable for entry into the trial at the discretion of the Investigator

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Faktoriel opgave
  • Maskning: Tredobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Placebo komparator: Placebo

Double-blind

Eksperimentel: Aero-001 lav dosis

Double-blind

Eksperimentel: Aero-001 høj dosis

Double-blind

Eksperimentel: Aero-002 lav dosis

Double-blind

Eksperimentel: Aero-002 høj dosis

Double-blind

Eksperimentel: AERO-001 medium dose

Double-blind

Eksperimentel: AERO-002 medium dose

Double-blind

Eksperimentel: AERO-007

Double-blind

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Bronchodilation - FEV1
Tidsramme: Change from baseline in FEV1 at 24 hours post-dose on Days 1 and 14
Change from baseline in FEV1 at 24 hours post-dose on Days 1 and 14
Bronchodilation - FEV AUC
Tidsramme: Change from baseline in FEV1 AUC(0-24 hours) on Days 1 and 14
Change from baseline in FEV1 AUC(0-24 hours) on Days 1 and 14
Bronchodilation - Peak FEV1
Tidsramme: Peak change in FEV1 within 4 hours post-dose on Days 1 and 14
Peak change in FEV1 within 4 hours post-dose on Days 1 and 14
Bronchodilation - time to onset of FEV1 >100mL
Tidsramme: Change in FEV1 >100mL from pre-dose on Days 1 and 14
Change in FEV1 >100mL from pre-dose on Days 1 and 14

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Pharmacokinetics - Cmax
Tidsramme: 0-24 hours on Days 1 and 14

Cmax (maximum plasma concentration)

0-24 hours on Days 1 and 14
Pharmacokinetics - AUC
Tidsramme: AUC(0-6 hours) on Days 1 and 14

AUC (area under the plasma concentration)

AUC(0-6 hours) on Days 1 and 14
Pharmacokinetics - Tmax
Tidsramme: Tmax on Days 1 and 14

Tmax (time to maximum concentration)

Tmax on Days 1 and 14
Treatment-emergent adverse events (TEAEs)
Tidsramme: Up to approximately Day 14

Number of participants with TEAEs

Up to approximately Day 14
Blood Pressure
Tidsramme: Up to approximately Day 14

Number of participants with markedly abnormal changes in Blood Pressure

Up to approximately Day 14
Heart Rate
Tidsramme: Up to approximately Day 14

Number of participants with markedly abnormal changes in Heart Rate

Up to approximately Day 14
12-lead ECG - QT Interval corrected for Heart Rate Using Fridericia's Formula (QTcF)
Tidsramme: Up to approximately Day 14

Number of participants with markedly abnormal changes in QTcF

Up to approximately Day 14
Clinical laboratory - Hematology
Tidsramme: Up to approximately Day 14

Number of participants with markedly abnormal changes in hematology parameters

Up to approximately Day 14
Clinical laboratory - Blood Chemistry
Tidsramme: Up to approximately Day 14

Number of participants with markedly abnormal changes in blood chemistry parameters

Up to approximately Day 14

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. november 2026

Primær færdiggørelse (Anslået)

1. juni 2027

Studieafslutning (Anslået)

1. september 2027

Datoer for studieregistrering

Først indsendt

14. oktober 2026

Først indsendt, der opfyldte QC-kriterier

19. oktober 2026

Først opslået (Faktiske)

26. oktober 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

19. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

17. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner